初级胆管胆结炎对传统疗法反应不完全,但对巴里西提尼布有完整的反应:一个病例报告
Gi Eun Kim1, Mariam Imran1, Sherif Mostafa1
1Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar, hamad.qa.
Case reports in hepatology
|December 31, 2025
概括
这项案例研究表明,巴里丁有效地使一次性胆道胆道炎患者的性酸酶水平正常化,该患者对其他治疗没有反应. 巴里西提尼布为管理这种进展性肝病提供了一个新的治疗选择.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 初级胆道胆炎 (PBC) 是一种渐进的自身免疫性肝脏疾病.
- 其并发症包括肝硬化和肝细胞癌.
- 治疗旨在延缓疾病的进展并改善结果.
研究的目的:
- 报告一个不完全响应标准治疗的PBC病例.
- 为了评估巴里西提尼布在治疗耐药PBC患者中的疗效.
- 突出巴里西提尼布在正常化性酸酶水平方面的潜力.
主要方法:
- 一个单一的案例研究设计.
- 一位患有PBC的患者接受了ursodeoxycholic酸,obeticholic酸和 fenofibrate.
- 由于反应不完整,治疗被切换为巴里西提尼布.
- 性酸酶水平作为关键的治疗反应标志物被监测.
主要成果:
- 患者对ursodeoxycholic 酸,obeticholic 酸和 fenofibrate 的反应不完全.
- 巴里西替尼治疗导致性酸酶水平持续正常化.
- 这表明生物化学标志物的治疗反应是完整的.
结论:
- 巴里西替尼在PBC患者中表现出显著的疗效,该患者对现有疗法反应不足.
- 性酸酶的持续正常化表明巴里西提尼布作为耐火性PBC的治疗选择的潜力.
- 需要进一步的研究来证实巴里西提尼布在PBC管理中的作用.
更多相关视频
相关概念视频
01:17Chronic Bowel Disorders: Introduction
900
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
900
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:29Chronic Pancreatitis II: Collaborative Care
563
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
563
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K